A Study to Evaluate the Bioequivalence (BE) and the Food Effect of TAK-438ASA Tablet
Condition: Healthy Volunteers
Intervention: TAK-438ASA; TAK-438; Aspirin
Intervention description: TAK-438ASA tablet.; TAK-438 tablet.; Aspirin enteric-coated tablet.
Intervention MeSH terms: Aspirin
Phase: Phase 1
Study type: Interventional
Primary purpose: Other
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Enrollment: 276.0
Sex: Male
Minimum age: 20 Years
Maximum age: 60 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Drug Therapy

Summary:

      The purposes of this study are to evaluate BE between a single-dose of TAK-438ASA tablet
      versus a single-dose combination of TAK-438 tablet 10 milligram (mg) and aspirin
      enteric-coated tablet 100 mg in Japanese healthy adult men (Study 1), and to evaluate the
      effects of food on the pharmacokinetics of TAK-438ASA tablet in Japanese healthy adult men
      (Study 2).
    

Eligibility criteria:

        Inclusion Criteria:

          1. In the opinion of the investigator or sub-investigator, participants are capable of
             understanding the procedures required for the study and complying with its
             requirements.

          2. Participants sign and date an informed consent form by themselves prior to the
             initiation of any study procedures.

          3. Japanese healthy men aged greater than or equal to (>=) 20 and less than or equal to
             (=<) 60, inclusive, at the time of consent.

          4. Body weight >=50 kilogram (kg) as well as body mass index (BMI) >=18.5 kilogram per
             meter square (kg/m^2) and =<25.0 kg/m^2 at screening test.

        Exclusion Criteria:

          1. Participants who received study drug within 16 weeks (112 days) prior to the start of
             study treatment in Period 1.

          2. Participants who received TAK-438 or aspirin in a previous study.

          3. Staffs at the study site and their family, or participants who depend on the
             study-related staffs at the study site (example, husband and wife, parents, children,
             brothers and sisters), or participants who may be constrained to consent to the study.

          4. Participants with uncontrolled and clinically significant neurological,
             cardiovascular, lung, hepatic, renal, metabolic, gastrointestinal, urinary or
             endocrine disease, or other abnormalities (except for diseases investigated) that
             might affect the study participation or impact the results of the study.

          5. Participants with a previous or current history of aspirin asthma (asthmatic attack
             induced by non-steroidal anti-inflammatory drugs, etc.).

          6. Participants with hypersensitivity for components of TAK-438 tablet or aspirin
             enteric-coated tablet, or salicylic acid-based products.

          7. Positive result in urinary test for illegal drug abuse at screening.

          8. Participants who have a history of illegal drug abuse or alcoholism within the past 2
             years prior to the screening visit, or who are not willing to refrain from alcohol
             consumption and drug use during the study period.

          9. Participants who ingested a medicine, a supplement or food forbidden to be used in
             combination during the specified time period.

         10. Participants with a current history or recent episodes (within the past 6 months) of
             gastrointestinal diseases (malabsorption, gastroesophageal reflux, peptic ulcer
             disease, erosive oesophagitis), frequent (at least once per week) heartburn or
             surgical intervention that might affect drug absorption.

         11. Participants with a history of cancer, except for basal cell carcinoma in remission
             for >=5 years prior to Day 1.

         12. Positive results at screening for hepatitis B surface antigen (HBsAg), hepatitis C
             virus (HCV) antibody, human immunodeficiency virus (HIV) antibody/antigen, or
             serological test for syphilis.

         13. Participants who have difficulties in blood draw from peripheral veins.

         14. Participants who had >=200 milliliter (mL) of whole blood drawn within 4 weeks (28
             days) prior to the start of study treatment in Period 1 or who had >=400 mL of whole
             blood drawn within 12 weeks (84 days) prior to the start of study treatment in Period
             1.

         15. Participants who had a total of >=800 mL of whole blood drawn within 52 weeks (364
             days) prior to the start of study treatment in Period 1.

         16. Participants who had blood components drawn within 2 weeks (14 days) prior to the
             start of study treatment in Period 1.

         17. Clinically significant abnormalities in electrocardiogram at screening or admission
             (Day -1).

         18. Participants with abnormal laboratory parameters suggestive of clinically significant
             underlying diseases or who have abnormal values in the following measures at
             screening: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) over the
             upper limit of normal.

         19. Participants who are unlikely to comply with the protocol or deemed ineligible due to
             other reasons by the principal investigator or other investigators.